[go: up one dir, main page]

WO2007015877A3 - Inhibitors of p38 kinase and methods of treating inflammatory disorders - Google Patents

Inhibitors of p38 kinase and methods of treating inflammatory disorders Download PDF

Info

Publication number
WO2007015877A3
WO2007015877A3 PCT/US2006/027896 US2006027896W WO2007015877A3 WO 2007015877 A3 WO2007015877 A3 WO 2007015877A3 US 2006027896 W US2006027896 W US 2006027896W WO 2007015877 A3 WO2007015877 A3 WO 2007015877A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
kinase
inhibitors
methods
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/027896
Other languages
French (fr)
Other versions
WO2007015877A2 (en
Inventor
Allen J Borchardt
Dana L Siegel
Elisabeth M M Gardiner
Shawn A Scranton
Daniel L Severance
Stewart A Noble
Boliang Lou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of WO2007015877A2 publication Critical patent/WO2007015877A2/en
Publication of WO2007015877A3 publication Critical patent/WO2007015877A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds and methods useful as inhibitors of p38 kinase for the treatment or prevention and treatment of diseases such as inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, and viral diseases.
PCT/US2006/027896 2005-07-20 2006-07-18 Inhibitors of p38 kinase and methods of treating inflammatory disorders Ceased WO2007015877A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70125505P 2005-07-20 2005-07-20
US60/701,255 2005-07-20

Publications (2)

Publication Number Publication Date
WO2007015877A2 WO2007015877A2 (en) 2007-02-08
WO2007015877A3 true WO2007015877A3 (en) 2007-06-07

Family

ID=37579471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027896 Ceased WO2007015877A2 (en) 2005-07-20 2006-07-18 Inhibitors of p38 kinase and methods of treating inflammatory disorders

Country Status (1)

Country Link
WO (1) WO2007015877A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
WO2011021678A1 (en) * 2009-08-21 2011-02-24 武田薬品工業株式会社 Fused heterocyclic compound
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CN102584688B (en) * 2012-01-13 2014-07-23 江苏中邦制药有限公司 Preparing method of 2,6-dichloro-3-nitropyridine
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3560926B1 (en) * 2016-12-21 2022-02-23 Ono Pharmaceutical Co., Ltd. 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors
PL3808747T3 (en) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
WO2020140054A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
JP7504822B2 (en) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 Pharmaceutical Compositions Containing Imidazopyridinone Compounds
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN116917288A (en) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 A kind of 7,9-dihydropurine derivative and its pharmaceutical use
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032649A1 (en) * 1999-10-29 2001-05-10 Boehringer Ingelheim Pharma Kg Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof
WO2002090347A1 (en) * 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2004024699A1 (en) * 2002-09-13 2004-03-25 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazolones and their use as cytokine inhibitors
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032649A1 (en) * 1999-10-29 2001-05-10 Boehringer Ingelheim Pharma Kg Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof
WO2002090347A1 (en) * 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2004024699A1 (en) * 2002-09-13 2004-03-25 Boehringer Ingelheim Pharmaceuticals, Inc. Benzimidazolones and their use as cytokine inhibitors
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAULON, CATHERINE ET AL: "A general and facile route to new trisubstituted purin-8-ones", SYNTHESIS , (13), 2227-2233 CODEN: SYNTBF; ISSN: 0039-7881, 2005, XP002426420 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2007015877A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007015877A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
IL257622B (en) Methods and compositions for the treatment of persistent infections
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2006104945A3 (en) Hepatitis c therapies
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2010062396A3 (en) Virus like particle compositions and methods of use
NZ542616A (en) P38 inhibitors and methods of use thereof
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2008011557A3 (en) Heteroaryl inhibitors of rho kinase
WO2008118823A3 (en) Compositions and methods for inhibition of the jak pathway
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
WO2007145704A3 (en) Gemcitabine combination therapy
IL195217A0 (en) Protein kinase inhibitors and uses thereof
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06787747

Country of ref document: EP

Kind code of ref document: A2